Skip to main content
RNXT
NASDAQ Life Sciences

RenovoRx的TIGeR-PaC第三期试验超过100名患者，接近招募完成

feedReported by GlobeNewswire
Sentiment info
Positive
Importance info
8
Price
$1.12
Mkt Cap
$40.315M
52W Low
$0.701
52W High
$1.45
Market data snapshot near publication time

summarizeSummary

RenovoRx宣布其第三期TIGeR-PaC临床试验达到一个重要里程碑，超过100名随机患者。这一进展使得该研究按计划进行，预计在2026年上半年完成招募，预计在2027年获得最终数据。对于一家小盘生命科学公司来说，推进第三期试验是一个关键的降风险事件，使公司更接近其新型药物-设备组合用于局部进展的胰腺癌的潜在商业化。独立数据监测委员会已经两次根据中期分析推荐继续试验，这进一步增强了信心。这一积极的运营更新是在最近的融资活动之后，包括1,000万美元的私募发行，这可能支持试验的继续推进。投资者现在将关注正式完成招募和随后的数据发布于2027年。

在该公告发布时，RNXT的交易价格为$1.12，交易所为NASDAQ，所属行业为Life Sciences，市值约为$4031.5万。 52周交易区间为$0.70至$1.45。 这则新闻被评估为积极市场情绪，重要性评分为8/10。 来源：GlobeNewswire。

show_chartPrice Chart

Share this article

Copied!

feed RNXT - Latest Insights

RNXT
Apr 27, 2026, 5:20 PM EDT
Filing Type: 424B3
Importance Score:
8
RenovoRx Registers Resale of 15.9 Million Shares from Recent Private Placement, Creating Significant Market Overhang
Sentiment: Negative
View Wiseek Article
RNXT
Apr 16, 2026, 5:10 PM EDT
Filing Type: S-3
Importance Score:
8
RenovoRx Registers Over $20 Million in Shares and Warrants for Resale by Private Placement Investors
Sentiment: Negative
View Wiseek Article
RNXT
Apr 08, 2026, 8:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
RenovoCath Device Secures First Japanese Patent Allowance, Bolstering Global IP and Asia Expansion
Sentiment: Positive
View Wiseek Article
RNXT
Mar 30, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
8
RenovoRx Reports $1.1M RenovoCath Revenue in First Full Year, Confirms Strong Cash Position & Trial Progress
Sentiment: Positive
View Wiseek Article
RNXT
Mar 27, 2026, 7:00 AM EDT
Filing Type: 8-K
Importance Score:
7
RenovoRx Appoints Dr. Ramtin Agah as Executive Chairman with $450K Base Salary and Bonus Eligibility
Sentiment: Positive
View Wiseek Article
RNXT
Mar 26, 2026, 8:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
RenovoRx's TIGeR-PaC Phase III Trial Surpasses 100 Patients, Nears Enrollment Completion
Sentiment: Positive
View Wiseek Article
RNXT
Mar 24, 2026, 9:16 PM EDT
Filing Type: 4
Importance Score:
7
RenovoRx CEO Invests $27,702 in Company's Recently Closed Private Placement
Sentiment: Positive
View Wiseek Article
RNXT
Mar 24, 2026, 9:15 PM EDT
Filing Type: 4
Importance Score:
8
CFO Mark Voll Invests $110,808 in RenovoRx Through Private Placement, Acquiring Stock and Warrants
Sentiment: Positive
View Wiseek Article
RNXT
Mar 23, 2026, 7:00 AM EDT
Filing Type: 8-K
Importance Score:
8
RenovoRx Secures $10M Private Placement to Fund Commercialization and Phase III Trial
Sentiment: Positive
View Wiseek Article
RNXT
Mar 18, 2026, 8:35 AM EDT
Source: GlobeNewswire
Importance Score:
8
RenovoRx Secures $10M Private Placement, Issuing ~10.6M Shares and Warrants
Sentiment: Neutral
View Wiseek Article